Anamorelin for Muscle Gain
Oral ghrelin-receptor agonist developed for cancer cachexia; approved in Japan as Adlumiz.
Why Anamorelin for muscle gain?
Anamorelin (ONO-7643) is an orally active selective ghrelin/GHSR-1a agonist. Approved in Japan (2021, Adlumiz, Ono Pharmaceutical) for cancer cachexia in NSCLC, gastric, pancreatic, and colorectal cancers. ROMANA-1/2 Phase 3 trials demonstrated lean-mass gains but failed handgrip-strength endpoints, leading to EMA refusal.
Muscle Gain context: Increasing lean mass via GH/IGF-1 axis, satellite-cell activity, or anabolic signaling. Anamorelin fits this goal because its category (Performance) and benefit profile align with the underlying mechanism.
Benefits relevant to muscle gain
- Increases lean body mass
- Improves appetite
- Oral bioavailability
Reference dosing by bodyweight
Anchored to the most-cited research dose (100000 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 62333–84333 mcg |
| 60–75 kg / 132–165 lb | 76500–103500 mcg |
| 75–90 kg / 165–198 lb | 93500–126500 mcg |
| 90–105 kg / 198–231 lb | 110500–149500 mcg |
| >105 kg / >231 lb | 127500–172500 mcg |
Side effects to weigh against muscle gain benefit
- Hyperglycemia
- Nausea
- Headache
Also researched for
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.